新的激素药物和针对非转移性激素敏感前列腺癌的综合策略:孤儿环境?
Fabrizio Di Costanzo1, Iolanda Santa Parisi2, Giuseppe Neola3
1Department of Medical Oncology, Università degli Studi di Napoli Federico II, Naples, Italy; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Chinese clinical oncology
|September 2, 2025
概括
第二代雄激素受体通路抑制剂 (ARPI) 在手术或放射治疗后对局部前列腺癌的辅助治疗具有前景. 需要进一步的研究来证实它们在新辅助环境中的有效性.
科学领域:
- 癌症学
- 尿瘤学
- 前列腺癌研究
背景情况:
- 大多数新诊断的前列腺癌 (PCas) 是非转移性,但15%的复发风险很高.
- 重点是局部/局部晚期疾病,以提高治愈率.
- 雄激素受体通路抑制剂 (ARPI) 和多塞可改善转移性疾病的结果.
研究的目的:
- 对局部,局部晚期和生化复发前列腺癌的ARPI研究进行审查.
- 研究早期使用ARPI加剧治疗以防止系统性传播.
- 检查前列腺癌早期治疗的新药和组合.
主要方法:
- 使用第二代ARPI搜索PubMed和MEDLINE进行局部/局部先进的PCa试验.
- 从主要的瘤学和泌尿瘤学会议中选的记录.
主要成果:
- 没有显著的结果支持第二代ARPI用于局部PCa的术后或新辅助治疗.
- 数据表明ARPI可能对前列腺切除术 (RP) 或放射治疗 (RT) 后的辅助患者有益.
结论:
- 临床试验应探索替代终点,例如无转移存活率 (MFS).
- 基因组测试的多臂试验可以促进进步.
- 研究应侧重于将ARPI与其他途径抑制剂或免疫反应调节剂结合使用.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


